Abstract 76P
Background
Colorectal cancer (CRC) is the third cause of cancer-related death worldwide. Surgery is the primary treatment followed by radiotherapy and/or chemotherapy which have toxic side effects and can be ineffective. 2D cell cultures and animal models have been used for CRC drug development. Still, they cannot recapitulate the human anatomy or physiology or predict drug efficacy, resistance and toxicity. Patient-derived organoids (PDO) are three-dimensional in vitro stem cell cultures that recapitulate the organs' cell lineage, functions and tumour heterogeneity retaining patients’ tumour antigens and faithfully predicting treatment response. Since PDOs lack the immune microenvironment needed to better predict patients' responses and resistance, we optimised an in vitro CRC organoids and immune cell co-culture protocol to rapidly and efficiently assess CD3- T cell interactions, activation and capacity to recognise and kill tumour organoids using bioengineered T cell engaging bispecific molecules.
Methods
We co-cultured CRC organoids, non-autologous stimulated CD3-T cells in suspension with T cell engager molecules HER2 and EGFR. At the end of each co-culture dose-response assay we assessed organoid viability, CD3-CD4-CD8 T cell viability, activation and killing by time-lapse live cell imaging, flow cytometry and ELISA.
Results
As HER2 and EGFR T cell engager doses were increased, the viability of the organoids substantially dropped. Moreover, CD4+CD25+CD69+ and CD8+CD25+CD69+ T cell populations were detected by flow cytometry in the presence of both T cell engagers' molecules but not in the controls. Finally, higher levels of Interferon-gamma cytokine were observed in the supernatant of co-cultured organoids with HER2 and EGFR molecules compared to the controls.
Conclusions
We have recreated the complex tumour cells and immune microenvironment interaction to successfully profile the efficacy, activity and crosstalk between HER2 and EGFR immune engager compounds, tumour organoids and immune cell subsets across a range of target organoid genotypes and a range of immune cell donors, aiming to replicate patients’ response and prioritise suitable immunotherapy candidates without the need for murine models.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Prof. Andrew Beggs Group - The University of Birmingham and AstraZeneca UK Limited.
Funding
AstraZeneca UK Limited.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract